EMA Authorised: Senshio (ospemifene) — Shionogi B.V.

View source ↗

Summary

The EMA authorised Senshio (ospemifene) for postmenopausal vulvar and vaginal atrophy. Marketing authorization was granted to Shionogi B.V. on 01/10/2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvar and Vaginal Atrophy

Drugs mentioned

• Senshio (ospemifene)

Snippet

Status: Authorised. Therapeutic area: Postmenopause. MAH: Shionogi B.V.. Decision date: 01/10/2024